Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the interest coverage ratio high or low?
The interest coverage ratio of -8.63x is in line with its 5-year average of -8.86x, near the high end of its 5-year range (-26.96x–-3.41x).
15.93% below its 12-month average of -7.44x.
Reported quarterly interest coverage; no daily interpolation. Q2 FY2026 (2026-06-30): -3.41x.
INTEREST COVERAGE RATIO
-8.63x
INTEREST COVERAGE RATIO AVG TTM
-7.44x
INTEREST COVERAGE RATIO AVG 3Y
-8.55x
INTEREST COVERAGE RATIO AVG 5Y
-8.86x
INTEREST COVERAGE RATIO AVG 10Y
N/A
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-15.93%
CURRENT VS 3Y AVG
-0.88%
CURRENT VS 5Y AVG
+2.59%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-6.38x
median of 528 covered companies
CURRENT VS SECTOR MEDIAN
-35.37%
vs the sector median at left
Ultragenyx Pharmaceutical Inc.
Market Cap
$1.42B
Interest Coverage Ratio
-8.63x
TTM Avg
-7.44x
3Y Avg
-8.55x
5Y Avg
-8.86x
Market Cap
$1.42B
Interest Coverage Ratio
0.60x
TTM Avg
0.60x
3Y Avg
0.60x
5Y Avg
0.60x
Market Cap
$1.44B
Interest Coverage Ratio
1.06x
TTM Avg
1.06x
3Y Avg
1.45x
5Y Avg
1.23x
Market Cap
$1.40B
Interest Coverage Ratio
-1753.94x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.45B
Interest Coverage Ratio
30.72x
TTM Avg
19.49x
3Y Avg
15.15x
5Y Avg
21.38x
Market Cap
$1.39B
Interest Coverage Ratio
7.70x
TTM Avg
6.59x
3Y Avg
5.19x
5Y Avg
6.41x
Market Cap
$1.46B
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | $1.42B | -8.63x | -7.44x | -8.55x | -8.86x |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 0.60x | 0.60x | 0.60x | 0.60x |
| Certara, Inc. (CERT)vs › | $1.44B | 1.06x | 1.06x | 1.45x | 1.23x |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | -1753.94x | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 30.72x | 19.49x | 15.15x | 21.38x |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 7.70x | 6.59x | 5.19x | 6.41x |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | N/A | N/A | N/A | N/A |
| GH Research PLC (GHRS)vs › | $1.48B | -131.05x | N/A | N/A | N/A |
Interest Coverage
-8.6x
Debt/Equity
N/A
Current Ratio
1.73
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2026-06-30 | -3.41x |
| 2026-03-31 | -8.05x |
| 2025-12-31 | -6.00x |
| 2025-09-30 | -12.08x |
| 2025-06-30 | -7.68x |
| 2025-03-31 | -9.97x |
| 2024-12-31 | -7.88x |
| 2024-09-30 | -8.40x |
| 2024-06-30 | -7.29x |
| 2024-03-31 | -10.43x |
| 2023-12-31 | -7.04x |
| 2023-09-30 | -8.21x |
| 2023-06-30 | -9.62x |
| 2023-03-31 | -9.86x |
| 2022-12-31 | -9.17x |
| 2022-09-30 | -15.52x |
| 2022-06-30 | -23.40x |
| 2022-03-31 | -20.75x |
| 2021-12-31 | -26.96x |
| 2021-09-30 | -10.35x |
| 2021-06-30 | -9.72x |
| 2021-03-31 | -12.66x |
| 2020-12-31 | -11.72x |
| 2020-09-30 | -5.86x |
| 2020-06-30 | -7.48x |
| 2020-03-31 | -14.93x |
| 2019-12-31 | -83.22x |
